Amir Fathi, MD, MPH, completed his medical education at Yale University School of Medicine and his residency at Massachusetts General Hospital. He obtained his fellowship in hemato-oncology at The Johns Hopkins Hospital, after which he transferred to Harvard Medical school as an Associate Professor of Medicine. Dr Fathi is also the Program Director of the Center for Leukemia at Massachusetts General Hospital Cancer Center.
Dr Fathi is a frequent speaker at the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) national meetings.
Speaking on novel therapies for acute leukemias
Dr Fathi’s research focus is centred on the development and translation of novel therapies in acute leukemias in a clinical setting. He currently leads multiple clinical trials at the Dana Farber/Harvard Cancer Center for patients with advanced leukemia and hematologic malignancies. His key interests are the targeting of FLT3, aurora kinases and antibody-drug conjugates.